Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited reported a significant increase in revenue by 1114.3% to $3,633,422 for the year ended June 30, 2025. Despite this growth, the company experienced a loss of $36,703,089, which is a 20.2% reduction from the previous year. The decrease in losses is attributed to reduced fair value movements in contingent consideration and share-based payments. The company’s net assets rose to $42,871,904, driven by capital raises and increased trade and other receivables, primarily due to a tax incentive related to research and development activities. Cash reserves also grew to $29,116,835, reflecting a stronger financial position.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the healthcare industry, focusing on theranostics, which combines therapeutics and diagnostics. The company is engaged in developing and commercializing radiopharmaceutical products for cancer treatment and diagnosis, aiming to enhance patient outcomes through innovative solutions.
Average Trading Volume: 3,240,897
Technical Sentiment Signal: Buy
Current Market Cap: A$65.04M
Find detailed analytics on RAD stock on TipRanks’ Stock Analysis page.